Targanta, Inc. is a biopharmaceutical company focused on developing and commercializing antibacterial
Targanta's latest-stage antibacterial drug, oritavancin, is a semisynthetic glycopeptide with potent
bactericidal activity against nearly all clinically relevant, difficult-to-treat Gram-positive
infections. Based on two successful Phase III clinical trials with oritavancin, Targanta intends
to file an NDA for complicated skin/skin structure infections in early 2008. Additional indications,
including nosocomial pneumonia and catheter-related bacteremia, will be sought on an ongoing
Targanta is also actively engaged in the development of novel antibacterial pro-drugs, based on
approved antibiotics with a proven track record, for the treatment and prevention of osteomyelitis
(bacterial infections of the bone). Product candidates are currently being tested in well-established
animal models of chronic osteomelyitis.
In addition to the development of our lead programs, Targanta maintains a discovery team focused
on developing additional drug candidates, including antibacterial agents aimed at the disruption
of nucleic acid metabolism. The Company's proprietary approach deciphers the mechanisms used by
bacterial viruses (phages) to subvert their hosts, thereby mimicking strategies devised through
four billion years of evolutionary pressure with regards to the selection of druggable bacterial
targets. High-throughput screening (HTS) with multicomponent enzymatic assays based on these
targets have enabled Targanta to identify new classes of proprietary small molecule antibacterial
As evidenced by a collective experience of over 50 INDs and 20 NDAs, Targanta's management team
has proven success in preclinical and clinical development and in regulatory approvals of drugs
including antibacterial agents.
Click here for an electronic copy of the Comprehensive Compliance Program.
Click here for an electronic copy of Targanta's Code of Conduct.